High rate of non-eligibility: Methodological factors impacting on recruitment for a multicentre, double-blind study of paediatric patients with major depressive disorder

Pharmacopsychiatry

Volumn 46, Issue 1, 2013, Pages 23-28

  Bliznak, L ^a   Berg, R ^a   Hage A ^a   Dittmann, R W ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

eligibility; major depression; paediatric patients; recruitment

Indexed keywords

ARIPIPRAZOLE; ATOMOXETINE; OLANZAPINE; RISPERIDONE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; COMORBIDITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; OUTCOME ASSESSMENT; PEDIATRICS; PRIORITY JOURNAL; SCHIZOPHRENIA; SCHOOL CHILD;

ADOLESCENT; CHILD; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HOSPITALIZATION; HUMANS; MALE; MULTICENTER STUDIES AS TOPIC; NEUROPSYCHOLOGICAL TESTS; PATIENT COMPLIANCE; PATIENT SELECTION; RESEARCH DESIGN; SUICIDE, ATTEMPTED; TREATMENT OUTCOME;

EID: 84872688096     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0032-1314806     Document Type: Article

References (29)

1. Lehmann B. Regulation (EC) No 1901/2006 on medicinal products for paediatric use & clinical research in vulnerable populations. Child Adolesc Psychiatry Ment Health: 2008; 2 37
2. Gruttadaro D. E., Miller J. E. NAM1 Policy Research Institute Task Force Report Children and Psychotropic Medications. (available on NAMIs web site at www.nami.org).www.fda.gov/ohrms/dockets/dailys/04/aug04/083104/ 04n-0330-ts00001-02-vol1.pdf
3. Publication European Commission Discussions in the Council are progressing well and the proposed Regulation on medicinal products for paediatric use will be discussed at the Health Council of 9 December 2005. [ http:// ec.europa.eu/ enterprise/ pharmaceuticals/ paediatrics/ medchild-key-en.htm ]
4. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use (1) [ http://europa.eu/eurlex/pri/en/oj/dat/2001/l-121/l-12120010501en00340044. pdf ]
5. Plueck J., Freund-Braier I., Hautmann C. et al. Recruitment in an indicated prevention program for externalizing behavior - parental participation decisions. Child Adolesc Psychiatry Ment Health: 2010; 4 15
6. Walson P. D. Patient recruitment: US perspective. Pediatrics. 1999; 104 619 622
7. Haberfellner E. M. Recruitment of depressive patients for a controlled clinical trial in a psychiatric practice. Pharmacopsychiatry: 2000; 33 142 144 (Pubitemid 30644556)
8. Partonen T., Sihvo S., Lonnqvist J. K. Patients excluded from an antidepressant efficacy trial. J Clin Psychiatry: 1996; 57 572 575 (Pubitemid 27056898)
9. Greil W., Ludwig-Mayerhofer W., Steller B. et al. The recruitment process for a multicenter study on the long-term prophylactic treatment of affective disorders. J Affect Disord: 1993; 28 257 265 (Pubitemid 23240263)
10. Bowen J., Hirsch S. Recruitment rates and factors affecting recruitments for a clinical trial of a putative anti-psychotic agent in the treatment of acute schizophrenia. Hum Psychopharmacol: 1992; 7 337 341 (Pubitemid 23076878)
11. Meyer zur Capellen K., Schmauß M., Messer T. Determinanten für den Ein- und Ausschluss von schizophrenen Patienten bei Phase III- und IV-Studien an einer psychiatrisch-psychotherapeutischen Versorgungsklinik. Available at: edoc.ub.uni-muenchen.de/10477/1/Meyer-zur-Capellen-Kathrin.pdf
12. Hewell K., Hoste R., le Grande D. et al. Recruitment for an adolescent bulimia nervosa treatment study. Int J Eating Disord: 2006; 39 594 597 (Pubitemid 44621814)
13. Emslie G. J., Ryan N. D., Wagner K. D. et al. Major depressive disorder in children and adolescents: clinical trial design and antidepressant efficacy. J Clin Psychiatry: 2005; 66 07 14 20 (Pubitemid 41345490)
14. Glickman S. W., Anstrom K. J., Lin L. et al. Challenges in enrollment of minority, pediatric, and geriatric patients in emergency and acute care clinical research. Ann Emerg Med: 2008; 51 775 780
15. Findling R. L., Robb A., Nyilas M. et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry: 2008; 165 1432 1441
16. Findling R. L., Nyilas M., Forbes R. A. et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry: 2009; 70 1441 1451
17. Kryzhanovskaya L., Schulz S. C., McDougle C. et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry: 2009; 48 60 70
18. Haas M., Unis A. S., Armenteros J. et al. 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol: 2009; 19 611 621
19. Dittmann R. W., Schacht A., Helsberg K. et al. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany. J Child Adolesc Psychopharmacol: 2011; 21 97 110
20. Michelson D., Faries D., Wernicke J. et al. Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics: 2001; 108 E83
21. Michelson D., Buitelaar J. K., Danckaerts M. et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry: 2004; 43 896 904 (Pubitemid 38808495)
22. Emslie G. J., Heiligenstein J. H., Hoog S. L. et al. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry: 2004; 43 1397 1405 (Pubitemid 39411040)
23. Emslie G. J., Heiligenstein J. H., Wagner K. D. et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolescent Psychiatry: 2002; 41 1205 1215 (Pubitemid 38338040)
24. LeBlanc J. C., Binder C. E., Armenteros J. L. et al. Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials. Int Clin Psychopharmacol: 2005; 20 275 283 (Pubitemid 41192148)
25. Reyes M., Buitelaar J., Toren P. et al. randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry: 2006; 163 402 410 (Pubitemid 44469381)
26. Bain J. Treatment of acute otitis media: are children entered into trials representative? Br J Gen Pract: 2001; 51 132 133 (Pubitemid 32117822)
27. Shilling V., Williamson P. R., Hickey H. et al. Processes in recruitment to randomized controlled trials of medicine for children (RECRUIT): a qualitative study. Hlth Technol Assess: 2011; 15 15
28. Busner J., Targum S. D. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont): 2007; 4 28 37
29. Posner K., Brown G. K., Stanley B. et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry: 2011; 168 1266 1277